Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: Evidence from a large population-based study

European Journal of Clinical Investigation

Volumn 44, Issue 10, 2014, Pages 933-939

  Corrao, Giovanni ^a   Soranna, Davide ^a   Merlino, Luca ^b   Mancia, Giuseppe ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Regione Lombardia   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Antihypertensive treatment; Brand name; Cardiovascular outcomes; Databases; Generic; Primary prevention

Indexed keywords

ANTIHYPERTENSIVE AGENT; GENERIC DRUG;

CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY PREVENTION; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 84908669984     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12326     Document Type: Article

References (25)

1. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51:149-62.
2. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 2005;142:891-7.
3. Håkonsen H, Horn AM, Toverud EL. Price control as a strategy for pharmaceutical cost containment-what has been achieved in Norway in the period 1994-2004? Health Policy 2009;90:277-85.
4. Kanavos P, Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 1999;15:519-33.
5. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol 2008;1:497-503.
6. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Saf 2001;10:295-300.
7. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
8. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010;70:335-41.
9. Committee for Proprietary Medicinal Products. Notes for Guidance on the Investigation of Bioavailability and Bioequivalence. London: European Medicines Evaluation Agency; 2001.
10. Shrank W, Cox E, Fischer MA, Mehta J, Choudhry NK. Patient perceptions of generic medications. Health Aff (Millwood) 2009;28:546-56.
11. Banahan BF, Bonnarens JK, Bentley JP. Generic substitution of NTI drugs. Formulary 1998;33:1082-96.
12. Gaither C, Kirking D, Ascione F, Welage L. Consumers' views on generic medications. J Am Pharm Assoc 2001;41:729-36.
13. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DJ, CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594-604.
14. Carter BL. Equivalence of generic and brand-name drugs for cardiovascular disease. JAMA 2009;301:1654.
15. Corrao G, Cesana G, Merlino L. Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy. BioMed Stat Clin Epidemiol 2008;2:117-25.
16. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
17. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A, for the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
18. Asplund K, Bonita R, Kuulasmaa K, Rajakangas AM, Schaedlich H, Suzuki K et al. Multinational comparisons of stroke epidemiology: evaluation of case ascertainment in the WHO MONICA stroke study. Stroke 1995;26:355-60.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
20. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology, 3rd edn. Chichester, UK: Wiley; 2000: pp 219-2.
21. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
22. Corrao G, Zambon A, Nicotra F, Fornari C, La Vecchia C, Mezzanzanica C et al. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes. Maturitas 2007;57:315-24.
23. Halpern MT, Khan ZM, Schmier JK, Burnier M, Carlo JJ, Cramer J et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48.
24. Mancia G, Parodi A, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 2011;29:1012-8.
25. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29:610-8.